Molbio Diagnostics shares rallied up to 6% to Rs 1,044 on Monday following a strong debut on Dalal Street. The stock moved higher soon after listing at Rs 980 on both the BSE and NSE, compared with the issue price of Rs 807 per share. The move from the opening price to the intraday high of Rs 1,044 represented a gain of approximately 6%, building on the listing premium already captured at the opening bell.
Listing Premium Surpasses Grey Market Expectations
Molbio Diagnostics debuted at a 21% premium to its IPO price of Rs 807, opening at Rs 980 on both main exchanges. This surpassed grey market expectations, which had indicated a listing premium of around 15%. The actual premium of approximately 21% therefore came in ahead of the implied levels seen in unofficial trading prior to listing.
Market commentary noted that the debut was considered healthy, with the listing valuation described as reasonable relative to peers. The combination of a better-than-expected premium and the subsequent rally to Rs 1,044 underlined the strength of demand for the shares on listing day.
Expert Commentary on Post-Listing Discipline
Market experts tracking Molbio Diagnostics highlighted the company’s position in molecular diagnostics and its expansion-led growth plans when discussing the listing. Shivani Nyati, Head of Wealth at Swastika Investmart, commented that Molbio Diagnostics had a healthy debut, listing at a premium of 21.4% to the issue price. She pointed to its leadership in molecular diagnostics, expansion-led growth strategy, and favourable industry prospects as elements backing interest in the shares.
At the same time, Nyati emphasised that investors should remain disciplined following the sharp initial gain seen on listing. She noted that while the listing valuation was reasonable relative to peers, caution was advisable after the early rally. She suggested a stop-loss level of Rs 900 for those invested in the stock, indicating a risk-management approach amid post-listing volatility. Investors looking to participate in such listings may consider whether to open demat account with a broker that offers access to new listings and IPO allotments.
IPO Size, Subscription Levels, and Anchor Investor Participation
The Molbio Diagnostics initial public offering (IPO) was sized at Rs 939.70 crore and received an overwhelming response from the market. The issue opened on August 10 and closed on August 12, drawing strong interest across investor categories.
Overall, the IPO was subscribed 70.26 times, reflecting significant oversubscription. Category-wise subscription details were as follows:
| Investor Category | Subscription (Times) |
|---|---|
| Qualified Institutional Buyers (QIBs) | 186.39x |
| Non-Institutional Investors (NIIs) | 49.80x |
| Retail Investors | 12.96x |
| Overall | 70.26x |
The IPO comprised a fresh issue of 25 lakh shares worth Rs 200 crore and an offer for sale of 92 lakh shares valued at Rs 739.70 crore. Prior to the public issue, the company allotted 34.87 lakh equity shares to 33 anchor investors at Rs 807 per share, the upper end of the IPO price band. Molbio Diagnostics is backed by Temasek and Motilal Oswal Private Equity. Kotak Mahindra Capital Company acted as the book-running lead manager, while KFin Technologies Ltd. served as the registrar.
Use of IPO Proceeds and Planned Capital Expenditure
Molbio Diagnostics has outlined specific plans for the utilisation of funds raised through the IPO. Key allocations include:
- Rs 125.12 crore earmarked for capital expenditure, including development of a research and development facility, a Centre of Excellence, and related office infrastructure.
- Rs 80.81 crore allocated towards plant, machinery, and other equipment for manufacturing facilities located in Goa and Visakhapatnam.
- Remaining proceeds to be used for general corporate purposes.
The total estimated utilisation of IPO proceeds stands at Rs 205.93 crore as per the company’s stated plan. Tracking such capital allocation details is relevant for those monitoring their stock investment decisions in newly listed companies over the medium term.
Business Profile and Diagnostic Offerings
Molbio Diagnostics Ltd., established in October 2000, is a global molecular diagnostics company engaged in developing, manufacturing, and commercialising rapid diagnostic solutions for both infectious and non-communicable diseases. The company is known for its proprietary Truenat platform a portable, battery-operated PCR-based molecular diagnostic system designed to deliver accurate test results within an hour.
Molbio provides testing solutions for more than 30 diseases through 43 diagnostic assays, covering areas such as tuberculosis, COVID-19, HIV, and Hepatitis, among others. This focus on rapid molecular testing forms the foundation of the company’s market position and contributed to the investor interest observed during the IPO process and on listing day. Investors tracking this stock can monitor its performance through their preferred trading platform for up-to-date price and volume data.
Leave a Reply